FDA Approves AbbVie’s Mavyret for Hepatitis C

August 8, 2017

The FDA has approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C who are without cirrhosis or with mild cirrhosis.

The drug could shorten the duration of treatment for many dialysis patients, the FDA said. Mavyret calls for eight weeks of treatment, compared to the previous standard of 12 weeks or more.

The approval includes treatment for patients on dialysis.

View today's stories